End Stage Kidney Disease: Clinical Trials

7 trials for End Stage Kidney Disease, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 recruiting. 7 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 37Completed 5, Recruiting 2
Phase 21Recruiting 1

Follow End Stage Kidney Disease: new trials by email Literature Review of End Stage Kidney Disease trials Research Report on End Stage Kidney Disease

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis
Empagliflozin 25 MG - Peritoneal Dialysis Complication, End Stage Kidney Disease
Phase 3RecruitingUniversity Health Network, Toronto202024-09-012026-05-01
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
CSL300, Placebo - End Stage Kidney Disease
Phase 2 / Phase 3RecruitingCSL Behring31102024-04-272026-09-21
Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2
PLS240, Placebo, Open-Label Extension PLS240 - Secondary Hyperparathyroidism, End Stage Kidney Disease
Phase 3CompletedPathalys Pharma4122023-05-152025-09-09
A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery
Sirolimus - Complication of Renal Dialysis, End Stage Renal Disease
Phase 3CompletedVascular Therapies, Inc.1362022-08-262026-10-06
Better Evidence for Selecting Transplant Fluids
Plasma-Lyte 148 (approx. pH 7.4) IV Infusion, 0.9% SODIUM CHLORIDE 9g/L injection BP - End Stage Kidney Disease, Delayed Graft Function
Phase 3CompletedThe University of Queensland8082018-01-262024-10-15
Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes
Sirolimus, AV Fistula Surgery, Sirolimus-eluting Collagen Implant (SeCI) - Complication of Renal Dialysis, End Stage Renal Disease
Phase 3CompletedVascular Therapies, Inc.2692015-11-012025-10-09
Effect of N-acetylcysteine (NAC) on Hydrogen Sulfide (H2S) in Chronic Kidney Disease (CKD)
N-acetylcysteine - Chronic Kidney Disease, Chronic Kidney Failure
Phase 3CompletedA.C. Abrahams282011-07-012012-10-26

Narrower conditions

Kidney Failure, Chronic (7)  ·  Arteriovenous Fistula (2)  ·  Renal Insufficiency, Chronic (2)  ·  Atherosclerosis (1)  ·  Coronary Artery Disease (1)  ·  Delayed Graft Function (1)  ·  Diabetes Mellitus (1)  ·  Hyperparathyroidism, Secondary (1)  ·  Myocardial Infarction (1)  ·  Peripheral Arterial Disease (1)

Broader conditions

Chronic Disease (7)  ·  Disease Attributes (7)  ·  Female Urogenital Diseases (7)  ·  Female Urogenital Diseases and Pregnancy Complications (7)  ·  Kidney Diseases (7)  ·  Male Urogenital Diseases (7)  ·  Pathologic Processes (7)  ·  Pathological Conditions, Signs and Symptoms (7)  ·  Renal Insufficiency (7)  ·  Urogenital Diseases (7)  ·  Urologic Diseases (7)  ·  Renal Insufficiency, Chronic (5)  ·  Cardiovascular Diseases (3)  ·  Vascular Diseases (3)  ·  Arteriovenous Malformations (2)

Interventions

Sirolimus (2)  ·  Acetylcysteine (1)  ·  Infusions, Intravenous (1)  ·  Plasma-lyte 148 (1)  ·  Plasmalyte A (1)  ·  Saline Solution (1)  ·  Sodium Chloride (1)  ·  clazakizumab (1)  ·  empagliflozin (1)

Sponsors

Vascular Therapies, Inc. (2)  ·  A.C. Abrahams (1)  ·  CSL Behring (1)  ·  Pathalys Pharma (1)  ·  The University of Queensland (1)  ·  University Health Network, Toronto (1)

Countries

United States (4)  ·  Australia (2)  ·  Bulgaria (2)  ·  Canada (2)  ·  Netherlands (2)  ·  Poland (2)  ·  Portugal (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  Argentina (1)  ·  Austria (1)  ·  Belgium (1)  ·  Brazil (1)  ·  China (1)  ·  Czechia (1)

Top investigators

Sriram Iyer, MD (2)  ·  A C Abrahams, MD (1)  ·  M C Verhaar, MD, PhD (1)  ·  Michael Collins, MBChB,FRACP,PhD (1)  ·  Steven Chadban, BMed(hons),FRACP,PhD (1)  ·  Sunita KS Singh, MD MSc FRCPC (1)

Results publications

PMID 32450917, PMID 35042554, PMID 37343576, PMID 38796655

NIH funding

2023 (1)